What is Shanghai Junshi Biosciences Co Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Shanghai Junshi Biosciences Co paidHK$0.0 Mil more to buy back shares than it received from issuing new shares.
It receivedHK$1,355.6 Mil from issuing more debt.
It paidHK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentHK$14.8 Mil paying cash dividends to shareholders.
It spentHK$15.7 Mil on other financial activities.
In all, Shanghai Junshi Biosciences CoearnedHK$1,325.1 Mil on financial activities for the
three
months ended in Mar. 2024.
Shanghai Junshi Biosciences Co Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shanghai Junshi Biosciences Co Cash Flow from Financing Chart
Shanghai Junshi Biosciences Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1,571.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (HKSE:01877) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Shanghai Junshi Biosciences Co's issuance of stock for the
three
months ended in Mar. 2024 was HK$0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Shanghai Junshi Biosciences Co's repurchase of stock for the
three
months ended in Mar. 2024 was HK$0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Shanghai Junshi Biosciences Co's net issuance of debt for the
three
months ended in Mar. 2024 was HK$1,355.6 Mil.
Shanghai Junshi Biosciences Co receivedHK$1,355.6 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Shanghai Junshi Biosciences Co's net issuance of preferred for the
three
months ended in Mar. 2024 was HK$0.0 Mil.
Shanghai Junshi Biosciences Co paidHK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Shanghai Junshi Biosciences Co's cash flow for dividends for the
three
months ended in Mar. 2024 was HK$-14.8 Mil.
Shanghai Junshi Biosciences Co spentHK$14.8 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Shanghai Junshi Biosciences Co's other financing for the
three
months ended in Mar. 2024 was HK$-15.7 Mil.
Shanghai Junshi Biosciences Co spentHK$15.7 Mil on other financial activities.
Shanghai Junshi Biosciences Co Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Shanghai Junshi Biosciences Co (HKSE:01877) Business Description
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01877 has been successfully added to your 